CLIMARA (estradiol) by Bayer is estrogen receptor agonists [moa]. Approved for estrogen [epc]. First approved in 1994.
Drug data last refreshed 3h ago · AI intelligence enriched 3h ago
CLIMARA is a transdermal extended-release estradiol patch approved in 1994 for hormone replacement therapy in menopausal women. It works as an estrogen receptor agonist to relieve vasomotor symptoms and other menopausal manifestations. The product delivers estradiol continuously through the skin, providing steady-state hormone levels.
Mature, stable revenue base with 19.6K annual claims signals a defensive position; brand team focus is on retention against generic competition and line extensions rather than growth.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on CLIMARA at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CLIMARA positions you in a mature, stable therapeutic area with strong established prescriber relationships and predictable patient base, ideal for commercial strategy and lifecycle management expertise. This is a defensive, efficiency-focused career opportunity rather than a high-growth launch platform; success depends on operational excellence, managed care negotiation, and competitive positioning against generics.